166 related articles for article (PubMed ID: 37952179)
1. Is underutilization of adjuvant therapy in resected non-small-cell lung cancer associated with socioeconomic disparities?
Rodriguez-Quintero JH; Kamel MK; Jindani R; Zhu R; Friedmann P; Vimolratana M; Chudgar NP; Stiles B
Eur J Cardiothorac Surg; 2023 Dec; 64(6):. PubMed ID: 37952179
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
4. Impact of travel distance on receipt of indicated adjuvant therapy in resected non-small cell lung cancer.
Eisenberg MA; Deboever N; Mills AC; Egyud MR; Hofstetter WL; Mehran RJ; Rice DC; Rajaram R; Sepesi B; Swisher SG; Walsh GL; Vaporciyan AA; Antonoff MB
J Thorac Cardiovasc Surg; 2024 May; 167(5):1617-1627. PubMed ID: 37696428
[TBL] [Abstract][Full Text] [Related]
5. Trends in Postoperative Intensity-Modulated Radiation Therapy Use and Its Association With Survival Among Patients With Incompletely Resected Non-Small Cell Lung Cancer.
Yu B; Jun Ma S; Waldman O; Dunne-Jaffe C; Chatterjee U; Turecki L; Gill J; Yendamuri K; Iovoli A; Farrugia M; Singh AK
JAMA Netw Open; 2022 Sep; 5(9):e2230704. PubMed ID: 36074462
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
7. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA.
Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
Future Oncol; 2023 Jan; 19(1):37-47. PubMed ID: 36662515
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer.
Naim Younes R; Gross JL; Abrao FG; Rodrigues Pereira J
Minerva Chir; 2013 Apr; 68(2):169-74. PubMed ID: 23612230
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.
Wang EH; Corso CD; Rutter CE; Park HS; Chen AB; Kim AW; Wilson LD; Decker RH; Yu JB
J Clin Oncol; 2015 Sep; 33(25):2727-34. PubMed ID: 26101240
[TBL] [Abstract][Full Text] [Related]
10. Postoperative radiotherapy with modern techniques does not improve survival for operable stage IIIA-N2 non-small cell lung cancer.
Predina J; Suliman R; Potter AL; Panda N; Diao K; Lanuti M; Muniappan A; Jeffrey Yang CF
J Thorac Cardiovasc Surg; 2023 May; 165(5):1696-1709.e4. PubMed ID: 36610886
[TBL] [Abstract][Full Text] [Related]
11. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study.
Lin ZZ; Shau WY; Shao YY; Yang YY; Kuo RN; Yang JC; Lai MS
Oncologist; 2012; 17(10):1294-302. PubMed ID: 22826374
[TBL] [Abstract][Full Text] [Related]
12. Underutilization of Systemic Therapy in Patients With NSCLC Undergoing Pneumonectomy: A Missed Opportunity for Survival.
Rodriguez-Quintero JH; Kamel MK; Dawodu G; Elbahrawy M; Vimolratana M; Chudgar NP; Stiles BM
JTO Clin Res Rep; 2023 Aug; 4(8):100547. PubMed ID: 37644968
[TBL] [Abstract][Full Text] [Related]
13. Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database.
Herskovic A; Mauer E; Christos P; Nagar H
J Thorac Oncol; 2017 Feb; 12(2):302-313. PubMed ID: 27746190
[TBL] [Abstract][Full Text] [Related]
14. Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database.
Gupta A; Omeogu C; Islam JY; Joshi A; Zhang D; Braithwaite D; Karanth SD; Tailor TD; Clarke JM; Akinyemiju T
Sci Rep; 2023 May; 13(1):8190. PubMed ID: 37210410
[TBL] [Abstract][Full Text] [Related]
15. Benefit of Adjuvant Chemotherapy for Patients Older Than 75 Years With Completely Resected p-Stage II-IIIA Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Using Japanese Nationwide Real-World Data.
Adachi H; Morohoshi T; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H;
Clin Lung Cancer; 2024 Jan; 25(1):61-71.e1. PubMed ID: 37914595
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of adjuvant therapy in T4 non-small cell lung cancer: An inverse probability of treatment weighting analysis.
Song YT; Yang SL; Fu Z; Liu XH; Yan SY; Wang ZH; Qin TT; Jiang HW; Jin Y; Yin P
Thorac Cancer; 2019 Mar; 10(3):472-482. PubMed ID: 30628189
[TBL] [Abstract][Full Text] [Related]
17. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.
Kassam F; Shepherd FA; Johnston M; Visbal A; Feld R; Darling G; Keshavjee S; Pierre A; Waddell T; Leighl NB
J Thorac Oncol; 2007 Jan; 2(1):39-43. PubMed ID: 17410008
[TBL] [Abstract][Full Text] [Related]
18. Update on adjuvant therapy in completely resected NSCLC patients.
Lim JU; Yeo CD
Thorac Cancer; 2022 Feb; 13(3):277-283. PubMed ID: 34898012
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
